Lilly’s CYRAMZA meets primary endpoint in phase 3 RELAY trial
The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with